drugset / Trial / NCT00193102

Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer

NCT00193102 ↗

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The lack of non-overlapping toxicities between the two drugs, the ease of all oral drug administration, and the possibility for antitumor synergy make exploration of this combination regimen attractive in women with previously treated metastatic breast cancer. This phase II trial will be performed in collaboration with the Minnie Pearl Cancer Research Network, a multicenter, community-based clinical trials group.

Timeline

Start
2001-04
Primary completion
2005-02
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule — Oral
Subject Thalidomide Other / unclassified — Oral

Indications